Analysis of function and signal transduction pathway of resistin using genetically-engineered animals
Analysis of function and signal transduction pathway of resistin using genetically-engineered animals
批准号:
17390260
负责人:
TERAUCHI Yasuo
金额:
$9.86万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2005
资助国家:
日本
项目状态:
已结题
起止时间:
2005 至 2006
中文摘要
点击翻译按钮获取中文摘要
英文摘要
We investigated the role of resistin in obesity-linked insulin resistance and central nervous system. Up-regulation of adiponectin by thiazolidinedione has been proposed to be a major mechanism of the thiazolidinedione-induced amelioration of insulin resistance linked to obesity. To test this hypothesis, we generated adiponectin knock-out (adipo-/-) ob/ob mice with a C57B/6 background. After 14 days of 10 mg/kg pioglitazone, the insulin resistance and diabetes of ob/ob mice were significantly improved in association with significant up-regulation of serum adiponectin levels. In contrast, insulin resistance and diabetes were not improved in adipo-/-ob/ob mice. After 14 days of 30 mg/kg pioglitazone, insulin resistance and diabetes of ob/ob mice were again significantly ameliorated. Interestingly, adipo-/-ob/ob mice also displayed significant amelioration of insulin resistance and diabetes. The serum-free fatty acid and triglyceride levels as well as adipocyte sizes in ob/ob and adipo-/- … More ob/ob mice were unchanged after 10 mg/kg pioglitazone but were significantly reduced to a similar degree after 30 mg/kg pioglitazone. Moreover, the expressions of TNFalpha and resistin in adipose tissues of ob/ob and adipo-/-ob/ob mice were unchanged after 10 mg/kg pioglitazone but were decreased after 30 mg/kg pioglitazone. Thus, pioglitazone-induced amelioration of insulin resistance and diabetes may occur via adiponectin-dependent and and-independent pathways.Adiponectin plays a central role as an antidiabetic and antiatherogenic adipokine. AdipoRl and AdipoR2 serve as receptors for adiponectin in vitro, and their reduction in obesity seems to be correlated with reduced adiponectin sensitivity. Adenovirus-mediated expression of AdipoRl and R2 in the liver of Lepr(-/-) mice increased AMP-activated protein kinase (AMPK) activation and peroxisome proliferator-activated receptor (PPAR)-alpha signaling pathways, respectively. Activation of AMPK reduced gluconeogenesis, whereas expression of the receptors in both cases increased fatty acid oxidation and lead to an amelioration of diabetes. Alternatively, targeted disruption of AdipoRl resulted in the abrogation of adiponectin-induced AMPK activation, whereas that of AdipoR2 resulted in decreased activity of PPAR-alpha signaling pathways. Thus, AdipoRl and R2 serve as the predominant receptors for adiponectin in vivo and play important roles in the regulation of glucose and lipid metabolism, inflammation and oxidative stress in vivo.We are also investigating the structure and role of resistin in central nervous system. Less
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Targeted disruption of AdipoR1 and Adipo2 causes abrogation of adiponectin binding and metabolic actions.
有针对性地破坏 AdipoR1 和 Adipo2 会导致脂联素结合和代谢作用失效。
DOI:
--
发表时间:
2007
期刊:
Nat Med 13(3)
影响因子:
--
作者:
[Yamauchi T, et al.]
通讯作者:
et al.
Adiponectin-dependent and - independent pathways in insulin-sensitizing and antidiabetic actions of thiazolidinedions.
噻唑烷二酮的胰岛素增敏和抗糖尿病作用中脂联素依赖性和非依赖性途径。
DOI:
--
发表时间:
2006
期刊:
Diabetes. 55 Suppl 2
影响因子:
--
作者:
[Kubota N, Yamauchi T, Tobe K, Kadowaki T.]
通讯作者:
Kadowaki T.
Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin dependent and independent pathway.
吡格列酮通过脂联素依赖性和非依赖性途径改善胰岛素抵抗和糖尿病。
DOI:
--
发表时间:
2006
期刊:
J. Biol. Chem. 281(13)
影响因子:
--
作者:
[N.Kubota, T.Noda et al.(total 20, 18th)]
通讯作者:
18th)
DOI:
10.1007/s00125-005-1806-3
发表时间:
2005-07-01
期刊:
DIABETOLOGIA
影响因子:
8.2
作者:
[Hara, K, Horikoshi, M, Kadowaki, T]
通讯作者:
Kadowaki, T
DOI:
--
发表时间:
2005
期刊:
Diabetes
影响因子:
7.7
作者:
[A. Tsuchida;T. Yamauchi;Sato Takekawa;Y. Hada;Yusuke Ito;Toshiyuki Maki;T. Kadowaki]
通讯作者:
A. Tsuchida;T. Yamauchi;Sato Takekawa;Y. Hada;Yusuke Ito;Toshiyuki Maki;T. Kadowaki
共 13 条
Elucidation of pathogenesis and treatment of islet mitochondrial dysfunction and inflammation under glucolipotoxicity
-
批准号:20H03733
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$11.4万
-
财政年份:2020
-
负责人:TERAUCHI Yasuo
-
依托单位:
Elucidation of the regulation of expression of receptors for incretin and PACAP in pancreatic beta cells
-
批准号:25670435
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$2.41万
-
财政年份:2013
-
负责人:TERAUCHI Yasuo
-
依托单位:
Establishing a base for tailor-made therapy on diabetes from the view point of the pancreatic beta cell mass
-
批准号:24390235
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$11.65万
-
财政年份:2012
-
负责人:TERAUCHI Yasuo
-
依托单位:
Regulation of pancreatic beta cell mass via glucokinase-dependent and independent pathways
-
批准号:21390282
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$11.65万
-
财政年份:2009
-
负责人:TERAUCHI Yasuo
-
依托单位:
Analysis of molecular mechanisms for impaired insulin secretion and beta-cell hyperplasia caused by lipotoxicity
-
批准号:15390285
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$9.47万
-
财政年份:2003
-
负责人:TERAUCHI Yasuo
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Got2基因对浆细胞样树突状细胞功能的调控及其在系统性红斑狼疮疾病中的作用研究
-
批准号:82371801
-
项目类别:面上项目
-
资助金额:47.00万元
-
批准年份:2023
-
负责人:周海波
-
依托单位:
Pik3r2基因突变在家族内侧颞叶癫痫中的作用及发病机制研究
-
批准号:82371454
-
项目类别:面上项目
-
资助金额:47.00万元
-
批准年份:2023
-
负责人:郝勇
-
依托单位:
基于FCER1G基因介导免疫反应探讨迟发性聋与认知障碍相关性的机制研究
-
批准号:82371141
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:陈颖
-
依托单位:
发展基因编码的荧光探针揭示趋化因子CXCL10的时空动态及其调控机制
-
批准号:32371150
-
项目类别:面上项目
-
资助金额:50.00万元
-
批准年份:2023
-
负责人:井淼
-
依托单位:
22q11.2染色体微重复影响TOP3B表达并导致腭裂发生的机制研究
-
批准号:82370906
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:代杰文
-
依托单位:
RET基因634位点不同氨基酸改变对甲状腺C细胞的影响与机制研究
-
批准号:82370790
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:叶蕾
-
依托单位:
lncGEI诱导湖羊卵巢颗粒细胞E2合成的分子机制
-
批准号:32372856
-
项目类别:面上项目
-
资助金额:50.00万元
-
批准年份:2023
-
负责人:李隐侠
-
依托单位:
KMT2A基因突变通过DNMT3靶向调控GBP2导致神经发育障碍的机制研究
-
批准号:82371867
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:王剑
-
依托单位:
综合医疗机构引入Gene-Xpert MTB/RIF技术早期发现传染性肺结核和耐药肺结核的研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2022
-
负责人:
-
依托单位:
NFATc3转录调控MMP14介导少突胶质细胞瘤血管新生促肿瘤恶变的机制研究
-
批准号:32100563
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:齐琳
-
依托单位: